|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_002973, 4506841|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||Predicted: 11 kDa|
|Application Notes||CCL2 antibody can be used for detection of CCL2 by Western blot at 1 - 2 µg/mL.|
|Reconstitution & Storage||CCL2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||CCL2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis.|
|Tissue Location||Expressed in the seminal plasma, endometrial fluid and follicular fluid (at protein level)|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CCL2 Antibody: CCL2, also known as monocyte chemotactic protein 1 (MCP1), belongs to the intercrine beta (chemokine CC) family. It is produced by a variety of cell types and is a potent chemoattractant for monocytes, memory T lymphocytes, and natural killer (NK) cells. It is upregulated during infection and inflammation. CCL2 is a potent basophil activator but does not affect eosinophils, whereas the related protein MCP2 stimulates both eosinophils and basophils. MCP3 has been shown to have the broadest range of influence. CCL2 has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis.
Carr MW, Roth SJ, Luther E, et al. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA 1994; 91:3652-6.
Conductier G, Blondeau N, Guyon A, et al. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J. Neuroimmunol. 2010; 224:93-100.
Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J. Clin. Invest. 1995; 95:1370-6
Bandinelli F, Del Rosso A, Gabrielli A, et al. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin. Exp. Rheumatol. 2012; 30:S44-9.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.